【导读】安罗替尼境外"仿制药"为假药 自2018年获批上市以来，安罗替尼已累计获批9项适应症，目前有五大适应症（非小细胞肺 癌、小细胞肺癌、软组织肉瘤、甲状腺癌、甲状腺髓样癌）被纳入国家医保目录，还有2项适 应症已递交上市申请并获受理。 该款药物在纳入医保前，患者一个月要花1万元左右。纳入医保后，以职工医保为例，一个月 的花销降至1000元左右。 不过，由于部分适应症暂未纳入报销范畴，那些所患适应症暂未纳入报销的患者仍面临一定 的经济压力。部分患者急于寻求治疗希望，又被网络上宣传的"境外低价"所吸引，就试图通 过非正规渠道购买安罗替尼。 据正大天晴法务总监介绍，2023年底就陆续有患者反映，在微信朋友圈等网络渠道流传着进 口版"福可维"，但企业并没有对海外进行相关授权。 中国基金报记者 卢鸰 2018年上映的电影《我不是药神》，现在有了一个完全不一样的现实版本，这次真的"不是 药神"。 12月22日下午，央视新闻曝光了一起代购的境外抗癌药有效成分为0的"假药案"，此事一度 登上百度热搜榜第一。 盐酸安罗替尼胶囊（福可维®）是中国生物制药核心企业正大天晴历时十余年自主研发的1类 创新药，其化合物专利荣获"中国专 ...

Group 1 - The Hong Kong Stock Connect innovative drug sector experienced its first pullback after three consecutive gains, with the popular Hong Kong Stock Connect innovative drug ETF (520880) dropping nearly 1% in the afternoon, indicating active buying interest despite the decline [1] - Major innovative drug stocks saw more declines than gains, with Kangfang Biopharma and China National Pharmaceutical Group both falling over 2%, while several others, including Yundingshinyao and Nuocheng Jianhua, dropped over 3% [1] - The recent policy initiatives from various cities, including Xi'an's plan to enhance the biopharmaceutical industry, aim to support the development of innovative drugs, particularly in areas like stem cell and peptide drugs [1] Group 2 - Changjiang Securities noted that the pharmaceutical industry is experiencing a policy cyclical phase, with supportive policies for the innovative drug sector gradually being implemented, indicating a new development cycle for innovative drugs [3] - Investors are encouraged to focus on high-quality innovative drug assets, particularly those with strong overseas potential, and to consider the Hong Kong Stock Connect innovative drug ETF (520880) as a low-entry point opportunity [3] - The index tracked by the Hong Kong Stock Connect innovative drug ETF has unique advantages, including a pure focus on innovative drug companies, a significant weight of over 72% in leading companies, and better risk control through reduced weight on less liquid stocks [3][4] Group 3 - The top ten holdings in the Hong Kong Stock Connect innovative drug ETF account for 72.57% of the total weight, showcasing the dominance of leading companies in the sector [4] - The ETF is positioned as a high-potential investment option for those looking to reduce volatility while still focusing on innovative drugs, with a significant portion of its holdings in traditional Chinese medicine to mitigate risks [4][5] - The Hong Kong Stock Connect innovative drug ETF has a scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan since its inception, making it the largest and most liquid ETF tracking the same index [5]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector experienced its first pullback after three consecutive gains, with the popular Hong Kong Stock Connect innovative drug ETF (520880) seeing a decline of nearly 1% in the afternoon, indicating active buying interest despite the drop [1]. Group 1: Market Performance - The leading innovative drug stocks mostly declined, with Kangfang Biopharma and China National Pharmaceutical Group both dropping over 2%, while several other stocks like Yunding Xinyao, Nuocheng Jianhua, and Ascentage Pharma-B fell more than 3% [1]. Group 2: Policy Developments - Xi'an recently released the "Implementation Plan for Promoting the Capacity Enhancement of the Biopharmaceutical Industry (2025-2027)," aiming to break through key core technologies in drug development across various fields, including stem cell drugs and peptide drugs [3]. - Multiple regions, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies this year to promote high-quality development in the innovative drug sector [3]. Group 3: Investment Insights - Changjiang Securities noted that the pharmaceutical industry is experiencing a certain policy cyclicality, with supportive policies for the innovative drug industry gradually being implemented, such as the introduction of insurance incremental funds and expedited clinical trial approvals [3]. - Investors are encouraged to focus on high-quality innovative drug assets, particularly those with "hard innovation" and strong overseas potential [3]. - The Hong Kong Stock Connect innovative drug ETF (520880) is highlighted as a top choice, with its underlying index, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, offering three unique advantages: purity, significant weight of leading companies, and better risk control [3][4][5]. Group 4: ETF Characteristics - The top ten innovative drug leaders account for over 72% of the ETF's weight, showcasing the strength of leading companies in the sector [4]. - The ETF has a total market capitalization of approximately HKD 12.87 billion, with the top ten holdings including companies like BeiGene (11.51% weight) and Innovent Biologics (10.19% weight) [6]. - For those looking to invest in innovative drugs while minimizing volatility, the only drug ETF in the market (562050) is recommended, which focuses on the top 50 A-share pharmaceutical companies, with about 60% in innovative drugs and 25% in traditional Chinese medicine [7].

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector experienced its first pullback after three consecutive gains, with the popular Hong Kong Stock Connect innovative drug ETF (520880) dropping nearly 1% in the afternoon, indicating active buying interest despite the decline [1][8]. Group 1: Market Performance - The innovative drug sector saw a majority of leading stocks decline, with Kangfang Biopharma and China National Pharmaceutical Group both dropping over 2%, while several others, including Yunding Xinyao and Nuocheng Jianhua, fell more than 3% [1][8]. - The Hong Kong Stock Connect innovative drug ETF (520880) has a significant concentration in leading stocks, with the top ten holdings accounting for over 72% of the index [4][12]. Group 2: Policy and Industry Support - Xi'an recently released a plan to enhance the biopharmaceutical industry's capabilities from 2025 to 2027, focusing on breakthroughs in key drug development technologies in areas such as stem cell drugs and peptide drugs [3][10]. - Various regions, including Beijing, Shanghai, Chongqing, and Sichuan, have introduced policies to promote high-quality development in the innovative drug sector this year [3][10]. - Changjiang Securities noted that the pharmaceutical industry is experiencing a policy cycle, with comprehensive support policies for the innovative drug sector gradually being implemented [9]. Group 3: Investment Opportunities - Investors are encouraged to consider the Hong Kong Stock Connect innovative drug ETF (520880) and its associated funds as a low-entry point opportunity, particularly focusing on "hard innovation" assets and those with strong overseas potential [9][11]. - The index tracked by the ETF, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, offers three unique advantages: it is purely focused on innovative drug companies, has a high concentration of leading firms, and employs measures to control risks associated with less liquid stocks [11][12]. - For those looking to mitigate volatility while investing in innovative drugs, the only drug ETF in the market (562050) and its associated funds are recommended, which also include a significant allocation to traditional Chinese medicine [12][13].

Investment Rating - The report maintains an "Overweight" rating for the industry [5] Core Insights - The pharmaceutical sector is experiencing a phase of oscillation and differentiation, with a recommendation to seize thematic rotation and bottom adjustment opportunities, particularly in the innovative drug supply chain and AI+ sectors [6][13] - The long-term growth driver for the pharmaceutical sector is technological innovation, with key focuses on "continuation of policy benefits," "breakthroughs in frontier technologies," and "international BD transactions" [6][13] - The report highlights the potential of new generation CTLA-4 therapies that address toxicity issues, thereby unlocking market potential [7] Summary by Sections Industry Overview - The pharmaceutical industry comprises 499 listed companies with a total market value of 71,291.29 billion [2] - The industry is currently valued at 25.8 times PE based on 2025 earnings forecasts, with a premium of 10.2% over the overall A-share market [22] Market Dynamics - The report notes a 14.49% return for the pharmaceutical sector since the beginning of 2025, underperforming the CSI 300 index by 1.60 percentage points [19] - Recent market movements show a decline in the pharmaceutical sector, with specific segments like pharmaceutical commerce and medical devices showing positive growth [19][6] Key Recommendations - Focus on companies involved in innovative drug development and AI applications, such as 恒瑞医药 (Hengrui Medicine), 中国生物制药 (China National Pharmaceutical Group), and 康方生物 (Kangfang Biopharma) [6][13] - The report emphasizes the importance of addressing clinical pain points and enhancing safety in new generation immuno-oncology drugs [7] Notable Companies - The report recommends several companies for investment, including 康方生物 (Kangfang Biopharma), 药明合联 (WuXi AppTec), and 泰格医药 (Tigermed) [7][30] - It highlights the performance of specific stocks, noting that the average decline for 中泰医药 (Zhongtai Medicine) was 2.51% this month, while it outperformed the industry by 0.68% this week [29][30]

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in the next 12 months [30]. Core Insights - The MSCI China Healthcare Index has increased by 51.9% since the beginning of 2025, outperforming the MSCI China Index by 24.3%. However, there has been a recent correction of 14% in the healthcare index, which is viewed as a rebalancing of valuations and expectations, creating better investment opportunities [1][3]. - The long-term trend of Chinese innovative drugs entering international markets is expected to continue, driven by competitive advantages such as higher early-stage R&D efficiency, faster clinical recruitment, and lower clinical costs. The focus for 2026 will be on the clinical progress and data release of pipelines that have already entered international markets [3]. - The impact of the recently enacted "Biological Security Act" on Chinese CXO companies is anticipated to be limited, as it does not affect Medicaid and Medicare procurement and has clear definitions regarding related parties. The revenue from U.S. government agencies for Chinese CXO companies is relatively small [3]. Summary by Sections Industry Overview - The recent industry correction is attributed to profit-taking and the market digesting previously high valuations, particularly in the innovative drug sector. This adjustment is seen as a rebalancing of valuations and performance, leading to more attractive investment opportunities [3]. - The report emphasizes the importance of monitoring the progress of products that have already entered international markets, as their clinical trials and data releases will serve as key catalysts for stock prices in 2026 [3]. Company Ratings and Valuations - The report recommends buying the following companies: - **Sihuan Pharmaceutical (1530 HK)**: Market cap of $8,178 million, target price of $37.58, with a potential upside of 44% [2]. - **Gusongtang (2273 HK)**: Market cap of $924.7 million, target price of $44.95, with a potential upside of 52% [2]. - **WuXi AppTec (2268 HK)**: Market cap of $10,782.4 million, target price of $74.00, with a potential upside of 6% [2]. - **China National Pharmaceutical Group (1177 HK)**: Market cap of $15,842.2 million, target price of $9.40, with a potential upside of 43% [2].

Core Viewpoint - The MSCI China Healthcare Index has increased by 51.9% from the beginning of 2025 to date, outperforming the MSCI China Index which rose by 24.3% [1] Group 1: Market Performance - The recent pullback in the healthcare sector has seen the MSCI China Healthcare Index decline by 14% since October [1] - The pullback is attributed to the digestion and rebalancing of valuations and expectations, creating a favorable investment window for future opportunities [1] Group 2: Investment Recommendations - The company recommends a cautious investment approach, focusing on undervalued stocks [1] - Specific stocks recommended for purchase include: - 3SBio Inc. (01530) - Genscript Biotech Corporation (02273) - WuXi AppTec Co., Ltd. (02268) - China National Pharmaceutical Group (01177) - All recommended stocks have a "buy" rating [1] Group 3: Future Outlook - The trend of innovative drugs entering international markets is expected to continue into 2026, with a focus on clinical progress and data validation of pipelines that have already gone abroad [1] - The recently enacted "Biosecurity Law" is anticipated to have limited impact on the operational aspects of Chinese CXO companies [1]

Core Viewpoint - The MSCI China Healthcare Index has increased by 51.9% from the beginning of 2025 to date, outperforming the MSCI China Index which rose by 24.3% [1] Group 1: Investment Recommendations - The company recommends a cautious investment approach, focusing on undervalued stocks [1] - Specific stocks recommended for purchase include: - 3SBio Inc. (01530) - Genscript Biotech Corporation (02273) - WuXi AppTec Co., Ltd. (02268) - China National Pharmaceutical Group (01177) - All recommended stocks have a "Buy" rating [1] Group 2: Market Trends - The healthcare sector has recently experienced a pullback, with the MSCI China Healthcare Index declining by 14% since October [1] - The recent pullback is attributed to the digestion and rebalancing of valuations and expectations, creating a better investment window for the future [1] Group 3: Future Outlook - Looking ahead to 2026, the trend of innovative drugs entering international markets is expected to continue [1] - The focus will be on the clinical progress and data validation of pipelines that have already entered international markets [1] Group 4: Policy Impact - The recently signed and effective "Biological Safety Law" is anticipated to have limited practical impact on the operations of Chinese CXO companies [1]

Group 1 - The report indicates that the A-share market is currently in a high-level oscillation state, with the index needing to transition from a liquidity-driven bull market to a fundamentals-driven bull market to stabilize above 4000 points [1][2] - The report assesses that most core A-share indices have a PE valuation percentile above 70%, indicating limited room for a cross-year rally due to the lack of further liquidity easing [1][2] - The report highlights that the current market structure is characterized by rapid sector rotation, with retail and social services sectors performing well, while the overall market lacks a clear mainline [1][2] Group 2 - The report emphasizes the importance of maintaining a relaxed investment mindset strategically, as only about 60% of the time in a year has a clear mainline, while the remaining 40% is often characterized by chaotic sector rotation [1][2] - The report suggests that tactical identification of clues is crucial, as new mainlines often emerge amidst confusion, and investors should avoid hasty decisions that could lead to losses [2] - The report notes that the current high-low switching market is nearing its end, and a new mainline is likely to form, with potential scenarios including tightening liquidity or new capital inflows [2] Group 3 - The report states that the A-share market's pricing structure is shifting from "new winning over old" to "new and old dancing together," indicating a focus on structural changes in technology and traditional industries [3] - It highlights that the technology sector is currently sensitive to positive news but more reactive to negative news, with AI applications being a key area for potential investment [3] - The report mentions that traditional industries are recovering from the negative impacts of the real estate sector, with profit growth expected in Q3 2025, suggesting a positive outlook for 2026 [3] Group 4 - The report indicates that the current market is experiencing a high degree of sector rotation, with the mainline clarity index at 48%, suggesting that the market is still in a chaotic state [1][2][3] - It emphasizes that the end of the high-low market phase is normal, and historical patterns suggest that such phases last about 3-4 weeks, with a focus on cross-year market positioning [1][2][3] - The report also notes that the technology sector is expected to regain its leading position in the market, particularly in the context of global AI trends and the performance of US tech stocks [3][4]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]